Bridge Medicines, a drug discovery company, has named Dr. Louis M. Renzetti as chief scientific officer. Recently, he was chief research and early development officer for Gotham Therapeutics. Bridge Medicines is backed by Deerfield Management and Bay City Capital.
o15 Capital Partners hires Capital One’s Rochelle Probst as managing director
29 October 2026 · 1 min read
HighPost Capital hires Quail Ridge founder Ron Sylvestri as managing director, marketing
28 October 2026 · 1 min read
Broad Sky Partners hires ex-Partners Group investor Henry Elefter as managing director
28 October 2026 · 2 mins read
HarbourVest names ex-Hamilton Lane executive Peter Larsen head of infrastructure distribution
27 October 2026 · 1 min read
Astira Capital Partners names ex-LTM executive Manoj Kothiyal head of AI
27 October 2026 · 1 min read
Franchise Equity Partners hires former Lithia & Driveway executive Chris Holzshu
27 October 2026 · 2 mins read
Eurazeo’s Christophe Bavière: Diversifying Europe’s mid-market
27 October 2026 · 7 mins read
